Health Canada Santé Canada

Protected B when completed

Submission of Comments
Portal Mock-Ups and Draft Guidance Document: Registration of Clinical Trials and Public Disclosure of Results Transparency of Health Canada-authorized clinical trials

All fields in this document are required*.

Comments submitted by

Full Name:

Company/Organisation Name (if applicable):

Telephone number:

Address:

E-mail Address:

Date:

Your personal information above will not be shared publicly.

Health Canada will summarize stakeholder comments received during this consultation in reports, such as a Summary of Comments or a What We Heard Report. Health Canada may make these reports publicly available.

Provide your feedback on the following questions and on both the draft guidance (Table 1) and the series of mock-up images of the proposed clinical trials portal (Table 2) using line numbers or section names.

Canada

1. Consider the way the information is being presented and organized on the series of mock-up images of the proposed clinical trials portal. Would the proposed layout and features allow you to find a clinical trial or set of search results that you would be looking for? For example, a particular medical condition or trial location?

2. Health Canada wants to ensure that information published in the portal is searchable in both official languages. This functionality will rely on Health Canada using controlled vocabularies for elements such as medical condition and intervention type. Tell us which controlled vocabularies you already use or prefer to use as part of your data management and transparency practices.

3. Where do you normally go online to look for information about clinical trials?

Protected B when completed

Table 1: Feedback on Draft Guidance Document

Section name or Line #*	Comment and Rationale	Proposed Revised Text

* Please refer to the PDF version of the document for line numbers

Canada

Protected B when completed

Table 2: Additional feedback on the mock-up images of the proposed clinical trials portal

Page # and section name	Comment and Rationale

Comments are due by April 24, 2023. Comments or questions should be directed to:

Bureau of Policy, Science and International Programs
Pharmaceutical Drugs Directorate
Health Products and Food Branch
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Ottawa, Ontario
K1A 0K9

E-mail: Policy_Bureau_Enquiries@hc-sc.gc.ca

Canada